Archives
Fosinopril Sodium Research Workflows
2026-08-19
Build more reproducible hypertension research and cardiovascular disease model workflows with Fosinopril sodium, an ACE inhibitor distinguished by phosphinic acid zinc-ion binding and prodrug activation. Practical guidance covers solution preparation, exposure design, renal hemodynamics modulation, blood pressure reduction, and troubleshooting across in vitro and in vivo studies.
Metoprolol Tartrate: Selectivity in Assay Design
2026-08-18
Metoprolol Tartrate is a β1-adrenergic blocking agent for dissecting cardiac signaling while limiting confounding nonselective β-receptor effects. This guide translates transplant-regeneration evidence into practical assay design, formulation, and interpretation decisions.
Honokiol at the Immunometabolism–Cancer Interface
2026-08-18
A translational framework for using Honokiol to investigate the intersection of NF-κB signaling, oxidative stress, angiogenesis, and CD8+ T-cell metabolic flexibility without overstating mechanistic evidence.
AG-120 (Ivosidenib): Translating IDH1 Biology
2026-08-17
AG-120 (Ivosidenib) offers translational researchers a direct way to interrogate mutant IDH1 biology, from 2-hydroxyglutarate reduction to differentiation. This perspective connects product-level assay design with emerging evidence that CD44-driven metabolic rewiring sustains oncometabolite production in IDH-mutant leukemia, helping researchers design more informative AML studies and resistance experiments.
H 89 2HCl in cAMP/PKA Assays
2026-08-17
H 89 2HCl provides a practical way to separate PKA-dependent phosphorylation from upstream cAMP production in neuronal and cell-signaling experiments. This guide translates its biochemical profile into assay workflows for neurite outgrowth, striatal neuron studies, and mechanistic follow-up of the Neuroligin 1–D2-MSN findings.
BAY-826 Workflow for Retinal Signaling Studies
2026-08-16
Build more informative retinal neuron-survival assays by pairing BAY-826 pharmacology with Müller cell co-culture, hypoxia, and orthogonal pathway readouts. This guide separates the reported biochemical potency of the compound from cellular-response variables, helping researchers improve dose selection, controls, and troubleshooting.
miR-1268a, CD36, and Angiotensin II Heart Failure
2026-08-15
A 2024 study identifies miR-1268a as a regulator of CD36-dependent fatty acid uptake, ATP production, and oxidative stress in Angiotensin II-treated AC16 cardiomyocytes. Its main contribution is a mechanistic link between microRNA dysregulation and metabolic impairment in an in vitro heart failure model, while its findings still require validation in primary cells and animal systems.
Biomimetic Chromatography for Lung Permeability
2026-08-14
The reference study evaluates immobilised artificial membrane liquid chromatography and open-tubular capillary electrochromatography, both coupled with mass spectrometry, as biomimetic models of pulmonary drug permeability. Its comparison of 53 structurally diverse compounds shows that IAM-LC provides a useful permeability-related retention model, while OT-CEC-MS adds complementary information about phospholipid composition and drug–membrane interactions.
Angiotensin III Workflows for RAAS Research
2026-08-14
Build reproducible RAAS, aldosterone, receptor-signaling, and neuroendocrine assays with Angiotensin III (human, mouse). A practical workflow also explains how recent spike–receptor binding findings can guide carefully controlled cross-domain experiments.
Intraperitoneal CAR Macrophage Programming by mRNA-LNP
2026-08-13
Gu and colleagues report a macrophage-targeted mRNA lipid nanoparticle system for programming CAR macrophages directly within the peritoneal cavity. By comparing 36 CAR configurations, single-cell transcriptomics, and checkpoint-blockade combinations, the study identifies CD3ζ–TLR4 intracellular domains as a design that promotes adaptive immune activation while remodeling the immunosuppressive tumor microenvironment.
Sex Differences in Angiotensin II Hypertension
2026-08-13
The reference study showed that chronic angiotensin II produced a substantially larger blood-pressure increase in conscious male mice than in female mice, while gonadectomy shifted these responses in opposite directions. By combining telemetry, baroreflex testing, and ganglionic blockade, the work connected sex-dependent hypertension with altered autonomic and reflex cardiovascular regulation.
DiscoveryProbe Protease Inhibitor Library: Assay Logic
2026-08-12
The DiscoveryProbe Protease Inhibitor Library enables systematic protease inhibition studies across biochemical, cellular, and phenotypic assays. This article uses a plant chemical-screening study to develop a rigorous strategy for distinguishing pathway-level effects from direct protease activity modulation.
BFH772 (VEGFR2 inhibitor) Protocol Guide
2026-08-12
BFH772 is a selective VEGFR2 inhibitor for research workflows that require targeted modulation of VEGFR2-associated angiogenic signaling, including endothelial and tumor angiogenesis models. It is best suited to assays using validated organic-solvent stocks and should not be selected for water-based formulations, broad-spectrum kinase screening, or studies requiring a defined in vivo dose regimen without additional optimization.
Angiotensin Peptides and SARS-CoV-2 Spike Binding
2026-08-11
The 2025 reference study identifies naturally occurring angiotensin peptides as sequence-dependent enhancers of SARS-CoV-2 spike binding to AXL, with Angiotensin IV also affecting ACE2 and NRP1. Its antibody-based binding experiments support a mechanistic link between renin–angiotensin peptide processing and viral receptor engagement, while leaving cellular infection and in vivo relevance to future validation.
Lisinopril Dihydrate: ACE Inhibitor Workflows
2026-08-11
Build reproducible ACE-inhibition assays and cardiorenal disease models with a water-compatible, nanomolar lisinopril dihydrate workflow. The guide connects biochemical target engagement to hypertension, heart failure, myocardial infarction, and diabetic nephropathy readouts while addressing selectivity and handling risks.
605 records 11/41 page Previous Next First page 上5页 1112131415 下5页 Last page